

October 18, 2022

Dear Valued Customer:

This letter is to inform you that effective January 1, 2023, Fresenius Kabi will no longer supply Bortezomib for Injection in the “**for intravenous use only**” presentation:

Product	Strength	NDC	Product Code	Product Description	Unit of Sale
<b>Bortezomib for Injection</b>	3.5 mg per vial	63323-0721-10	761210	Single Dose Vial <b>(for intravenous use only)</b>	1 vial

We will continue to manufacture Bortezomib for Injection in the “**for subcutaneous or intravenous use**” presentation as outlined below:

Product	Concentration	NDC	Product Code	Product Description	Unit of Sale
<b>Bortezomib for Injection</b>	3.5 mg per vial	63323-0821-10	861210	Single Dose Vial <b>(for subcutaneous or intravenous use)</b>	1 vial

If you have any questions, please contact your sales representative or Customer Service at (888) 386-1300.

For clinical or technical questions regarding Fresenius Kabi products, please contact the Fresenius Kabi USA Vigilance & Medical Affairs Department at 1-800-551-7176, Monday - Friday, between the hours of 8 a.m. and 5 p.m. (CST)

Fresenius Kabi is committed to supplying our customers with oncology products, and we apologize for any inconvenience this may cause.

Sincerely,



Scott Bojan  
 Senior Marketing Manager, Oncology  
 Fresenius Kabi USA, LLC